Comparison · NCT00550615-deaths
Phase I Participants vs Phase II Participants: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Phase I Participants vs Phase II Participants: deaths from any cause. Trial comparisons, record NCT00550615-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00550615-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0714 | 0.0127 | 0.315 | wilson | |
| Risk in group 2 | 0.211 | 0.0851 | 0.433 | wilson | |
| Risk difference, group 1 minus group 2 | -0.139 | -0.37 | 0.135 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.339 | 0.0424 | 2.72 | log | |
| Odds ratio, group 1 over group 2 | 0.288 | 0.0285 | 2.92 | log | |
| Number needed to treat, for one fewer death from any cause on Phase I Participants than on Phase II Participants | 7.19 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Phase I Participants | All participants that were dose were monitored for adverse events. | 1 | 14 | EG000 |
| Group 2 | Phase II Participants | All participants that were dose were monitored for adverse events. | 4 | 19 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Adverse Events were collected from the time of enrollment until 30 days after the participant completed study treatment.
Source ClinicalTrials.gov
Trial
- Title
- Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
- NCT number
- NCT00550615
- Phases
- PHASE1, PHASE2
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Dasatinib, Dasatinib Maximum Tolerated Dose
- Lead sponsor
- University of Nebraska
- Results first posted
- 2019-02-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00550615?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00550615-deaths